Tag: Atrial Fibrillation
-
Comparative Evaluation of Prognostic Scoring Systems for Atrial Fibrillation Recurrence
Introduction Atrial fibrillation (AF) is a leading cause of stroke, heart failure, and mortality worldwide. Beyond rhythm control, identifying which patients are most likely to experience AF recurrence after intervention is crucial for guiding therapy, follow-up, and lifestyle decisions. Prognostic scoring systems have emerged to stratify recurrence risk, but their performances vary across populations and…
-
Comparative Evaluation of Prognostic Scoring Systems for Recurrence After Atrial Fibrillation Treatments
Introduction Atrial fibrillation (AF) remains a leading cause of stroke, heart failure, and cardiovascular mortality worldwide. Beyond rhythm control decisions, clinicians increasingly rely on prognostic scoring systems to estimate the risk of AF recurrence after treatment modalities such as rate control, rhythm control, catheter ablation, or surgical interventions. This article provides a comparative evaluation of…
-
Comparative Evaluation of Prognostic Scoring Systems for Atrial Fibrillation Recurrence After Ablation
Introduction Atrial fibrillation (AF) is a leading cause of stroke, heart failure, and cardiovascular morbidity. While rhythm control strategies—including catheter ablation—offer symptom relief and improved quality of life, recurrence after ablation remains a clinically important challenge. Over the past decade, several prognostic scoring systems have been proposed to predict AF recurrence following ablation or therapeutic…
-
What Is Holiday Heart Syndrome? A Cardiologist Explains
What Is Holiday Heart Syndrome? Holiday Heart Syndrome is a term used to describe abnormal heart rhythms—usually atrial fibrillation or other arrhythmias—that occur during the holiday season. It’s linked to a combination of festive activities, stress, alcohol consumption, dehydration, and dietary changes. While the name might imply a purely seasonal issue, the underlying drivers are…
-
Daily Coffee May Benefit People with Atrial Fibrillation, New Study Finds
New evidence reshapes the coffee and atrial fibrillation conversation For years, people living with atrial fibrillation (AFib) were told to limit or avoid caffeine, under the belief that coffee could worsen irregular heart rhythms. A new study challenges that longstanding guidance, suggesting that daily coffee consumption may be beneficial for some individuals with AFib. While…
-
Daily coffee drinking may be beneficial for people with atrial fibrillation, new study finds
New findings challenge old cautions about caffeine and atrial fibrillation For years, people living with atrial fibrillation (AF) were often advised to limit or avoid caffeine, with the worry that coffee could trigger episodes of irregular heart rhythms or worsen symptoms. A new study, however, presents evidence that daily coffee drinking may be beneficial for…
-
Daily Coffee Drinking May Benefit People With Atrial Fibrillation, New Study Finds
Understanding the Finding: Coffee and Atrial Fibrillation For years, patients living with atrial fibrillation (AFib)—a condition marked by persistent irregular heartbeats—were told to limit or avoid caffeine. The concern was that caffeine could trigger palpitations or worsen symptoms. A growing body of research, however, is painting a more nuanced picture. A recent study from researchers…
-
DARE-AF Dapagliflozin Fails to Reduce AF Burden After Catheter Ablation
New Findings Question SGLT2 Inhibitors for Post-Ablation AF Recurrence In a development that surprises many in the cardiology community, the DARE-HF trial examined whether the SGLT2 inhibitor dapagliflozin could reduce the burden of atrial fibrillation (AF) after catheter ablation. Conducted in patients who recently underwent ablation for AF, the study aimed to determine if adding…
-
DARE-AF: Dapagliflozin Fails to Reduce AF Recurrence After Catheter Ablation
Overview: DARE-AF Trial Questions SGLT2 Inhibition After Ablation The latest findings from the DARE-AF trial suggest that dapagliflozin, an SGLT2 inhibitor, does not reduce the burden of atrial fibrillation (AF) after catheter ablation. Conducted in a diverse patient population, the study aimed to determine whether adding dapagliflozin to standard post-ablation care could lower AF recurrence…
-
DARE-AF Trial: Dapagliflozin Fails to Reduce AF Burden After Ablation
Overview: Aiming to Lower AF Recurrence With SGLT2 Inhibition The DARE-HF trial, conducted in New Orleans, tested whether dapagliflozin, an SGLT2 inhibitor, could reduce the burden of atrial fibrillation (AF) after catheter ablation. AF remains a leading heart rhythm disorder, and recurrence after ablation poses a persistent challenge for patients and clinicians. While SGLT2 inhibitors…